Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis
Authors' conclusion
The preliminary evidence suggested that JAKi is a relatively safe and effective alternative for JDM patients. Cytokine profiles could well reflect the inflammatory status of JDM patients.
Study context
- Population
- JDM patients, Affiliated Children's Hospital of Capital Institute of Pediatrics (China), November 2017–December 2021
- Participants
- 101 / 128 / 30
- Exposure
- Janus Kinase Inhibitor (JAKi) vs Cytokine JDM vs Controls
- JAKin = 101
- Cytokine JDMn = 128
- Controlsn = 30reference
- Outcome
- Outcomes on JAKi
- Follow-up
- Median 19 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Improved rashes
65.5%
Eliminated GC
39.6%
Observational data: associations, not effects.
Further findings
Cytokines in active JDM
- Cytokines significantly elevated in active JDM
- 12/34
- IL-1RA over 793 times the mean of normal values
- 793
- Active JDM with only rashes had lower cytokine levels than active JDM with multiple phenotypes
- Anti-NXP2-positive active patients had lower cytokine levels than anti-NXP2-negative
Six-cytokine panel differentiating active vs stable status
- AUC
- 0.8486
- P
- P < 0.05
Safety
Serious adverse events
- No serious adverse events reported
Potential side effects of JAKi
- Abnormal leukopoenia
- 14/95
- Cough
- 16/83
- Affected over 10% of the JDM patients
Original publication
Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. Rheumatology (Oxford). Published 29 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →